Search

Displaying results 931 - 940 of 9323 in total
  1. Drug

    Stem bromelain

    go.drugbank.com/drugs/DB12249
    Approved

    The primary therapeutic use for which stem bromelain is currently and formally indicated is as a burn wound eschar debridement agent that has been approved by the EMA since 2012 and marketed under the … This action allows bromelain to demonstrate a wide range of therapeutic benefits ranging from cardiovascular to anticancer therapy - but the specific mechanisms of action by which it can elicit these effects

  2. Drug

    Gepotidacin

    go.drugbank.com/drugs/DB12134
    ApprovedInvestigational

    [L52680,L52685] In December later the same year, the FDA approved another indication for gepotidacin for the treatment of uncomplicated urogenital gonorrhea. [L54803] … [A273755] By inhibiting two distinct bacterial enzymes, a lower potential for the development of resistance to gepotidacin is expected.

  3. Drug

    Allopurinol

    go.drugbank.com/drugs/DB00437
    ApprovedInvestigational

    Allopurinol is a xanthine oxidase enzyme inhibitor that is considered to be one of the most effective drugs used to decrease urate levels and is frequently used in the treatment of chronic gout [A36705 … It was initially approved by the FDA in 1966 [L5674] and is now formulated by several manufacturers [L5677].

  4. Drug

    Bretylium

    go.drugbank.com/drugs/DB01158
    Approved

    The primary mode of action for bretylium is thought to be inhibition of voltage-gated K(+) channels. … Recent evidence has shown that bretylium may also inhibit the Na,K-ATPase by binding to the extracellular K-site.

  5. Drug

    Nitrous oxide

    go.drugbank.com/drugs/DB06690
    ApprovedInvestigationalVet approved

    It is known as "laughing gas" due to the euphoric effects of inhaling it, a property that has led to its recreational use as an inhalant drug. … Nitrous oxide, commonly known as "laughing gas", is a chemical compound with the chemical formula N2O.

    Mixtures: OXICALM® MEZCLA MEDICINAL DE OXIGENO: OXIDO NITROSO
  6. Drug

    Eliglustat

    go.drugbank.com/drugs/DB09039
    ApprovedInvestigational

    In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs. … [L41404,A7634] Enzyme replacement continues to be the standard of care for the treatment of type 1 Gaucher disease ([imiglucerase], [velaglucerase alfa], [taliglucerase alfa]); however, oral substrate

  7. Drug

    Butamben

    go.drugbank.com/drugs/DB11148
    ApprovedWithdrawn

    The FDA removed all parenteral butamben products from the market, possibly due to the poor solubility of this drug.[A254247,L43942] … Due to its very low water solubility, butamben is considered to be suitable only for topical anesthesia.

  8. Drug

    Gallium citrate Ga-67

    go.drugbank.com/drugs/DB06784
    Approved

    Gallium citrate Ga 67 is the citrate salt of the radioisotope gallium Ga 67. … Although the mechanism is unknown, gallium Ga 67 concentrates in lysosomes and is bound to a soluble intracellular protein in certain viable primary and metastatic tumors and focal sites of inflammation

  9. Drug

    Isosorbide mononitrate

    go.drugbank.com/drugs/DB01020
    ApprovedInvestigational

    [L11698] It is available in oral tablets generically and under the brand name ISMO and Monoket. The extended-release forms of the drug are also available generically and under the brand name Imdur. … [T28] First approved by the FDA in 1991,[L11743] isosorbide mononitrate is used for the prevention and management of angina pectoris caused by coronary artery disease; however, the onset of action of

    Synonyms: Mononitrato de isosorbida
  10. Drug

    Normethadone

    go.drugbank.com/drugs/DB11609
    ApprovedIllicit

    It is marketed in Canada by Valeant under the tradename Cophylac.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome